# A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03969719` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03969719](<https://clinicaltrials.gov/study/NCT03969719>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03969719

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

## Technical summary

Registry record NCT03969719. Randomized; double masking; primary purpose basic science. Start 2019-07-18 (actual); primary completion 2021-03-02 (actual). Results posted on 2022-05-11.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose basic science
- Phase: Phase 2
- Enrolled: 164 participants (enrolled count; ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Started: 2019-07-18 (actual) (ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Primary completion: 2021-03-02 (actual) (ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Completion: 2021-03-30 (actual) (ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Results first posted: 2022-05-11 (ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03969719, source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03969719-2022-05-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
- Condition: Non-alcoholic Steatohepatitis
- Intervention (Drug): Placebo
- Intervention (Drug): PF-06835919
- Intervention (Drug): PF-06835919
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: 6c481c8e01a65827b9d995ee496fae10333006d2381ef993a867d1f2f76518db
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
